New Paradigms of Care in Hypertrophic Cardiomyopathy

The landscape of diagnosis, risk stratification, and treatment of hypertrophic cardiomyopathy (HCM) has rapidly evolved over the last decade, especially with the U.S. FDA approval of the first-in-class cardiac myosin inhibitor in 2022. This session will review the contemporary standards of care for patients with hypertrophic cardiomyopathy, including insights in clinical presentation, management of arrhythmias, sudden death risk stratification, use of novel therapies, and emerging science in HCM.